PerkinElmer Highlights Innovative Solutions for Enabling Personalized Medicine in Cancer Research at AACR 2012

WALTHAM, Mass.--(BUSINESS WIRE)--

At the American Association for Cancer Research 2012 Annual Meeting (Booth #2306), PerkinElmer, Inc., a global leader focused on improving the health and safety of people and the environment, today announced that it will be showcasing numerous solutions, posters and knowledge-sharing events in support of cancer-focused personalized medicine research.

"PerkinElmer remains committed to the fight against cancer through enabling personalized medicine solutions that allow researchers to find, understand, and act upon the causes and processes of the disease, said Kevin Hrusovsky, President, Life Sciences & Technology, PerkinElmer. We are passionate about helping academic, biopharma and clinical researchers to achieve new insights for discovering advanced therapeutics and diagnostics to reduce the threat of cancer. Our solutions in Next Generation Sequencing, advanced cellular, in vitro and in vivo imaging, automation instrumentation, and reagent technologies, provide researchers the critical tools they need to combat this deadly disease."

On the evening of Tuesday, April 3, PerkinElmer will be hosting an event, entitled "The Revolutionizing Medicine Rock 'n' Roll Reception," featuring distinguished speakers who are committed to the fight against cancer, discussing how personalized medicine is changing research and treatment of the disease. The event will also feature performances by Molecular Groove, the PerkinElmer band.

Featured speakers at the event include clinical, academic and industry thought leaders in personalized medicine for cancer, such as:

PerkinElmer solutions for enabling personalized medicine-based cancer research on display at AACR 2012 include:

PerkinElmer instruments and software featured at AACR include:

PerkinElmer poster presentations at AACR 2012 include:

About PerkinElmer, Inc.

PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The Company reported revenue of approximately $1.9 billion in 2011, has about 7,000 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at http://www.perkinelmer.com.

Read this article:
PerkinElmer Highlights Innovative Solutions for Enabling Personalized Medicine in Cancer Research at AACR 2012